Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria
Toronto, Ontario, December 23, 2020 – Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (CSE:PSYC, OTCQB:DCNPF, FRANKFURT:5U9) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share that it has shipped its first batch of Amanita Muscaria extract to its CRO partner to commence the Pre-Clinical trials.
The Company sent 108 grams of highly concentrated Amanita Muscaria extract to its CRO’s lab to begin the first phase of its Pre-Clinical Trial. This first batch of Amanita extract will be used in a study to determine the Maximum Tolerated Dose (MTD). The goal of the study is to determine the highest dose of our extract that will not cause unacceptable side effects or an overt toxicity in a defined period. This is a key first step in determining the appropriate dosage for our future products.
Jeff Stevens, CEO of the Company says, “This is a major milestone for Psyched Wellness! We have now officially commenced our Pre-Clinical Trials to determine the safety, efficacy, and safe dosage levels for Amanita Muscaria. This is a key step, as it is the foundation off which we can apply to the FDA for a New Dietary Ingredient (NDI) and Health Canada for a Natural Health Product Number (NHPN) for our Amanita Muscaria supplement. It will also provide the IP required to focus our team’s attention on studying other more clinical uses of Amanita Muscaria for mental and physical health issues.”